EMA Recommends Approval of the Marketing Authorisation for Tagraxofusp
It is intended for first-line treatment of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive type of acute myeloid leukaemia
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
EMA Recommends Granting a Marketing Authorisation for a Biosimilar Bevacizumab, Onbevzi
It received a positive opinion for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell carcinoma, epithelial ovarian cancer and carcinoma of the cervix
Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of Adverse Outcomes From SARS-CoV-2 Infection
Systemic inflammation is a key driver of mortality in SARS-CoV-2 in cancer patients and biomarkers of inflamation may be used to identify patients at increased risk
Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients with Early Stage Colon Cancer
Innovative risk-assessment tool measures the patient’s local immune response to the tumour
Pembrolizumab Combinations Show Promise in mCRPC
All of the pembrolizumab regimens were safe in patients with metastatic castration-resistant prostate cancer
Pembrolizumab Plus Axitinib Outperforms Sunitinib in Patients with Metastatic Renal Cell Carcinoma
KEYNOTE-426 data from patients enrolled in Eastern Asia is consistent with that of the overall population
Promising Results Observed with Front-line Sintilimab Plus a Bevacizumab Biosimilar in Patients with Advanced HCC
Safety has already been demonstrated for sintilimab, a monoclonal antibody targeting the PD-1, plus a bevacizumab biosimilar as first-line treatment for advanced hepatocellular carcinoma
Front-line CS1001 Plus Platinum-Based Chemotherapy Delivers Substantial Benefit in Advanced Non-Small Cell Lung Cancer
Improved outcomes following first-line CS1001/chemotherapy were observed in Chinese patients with both squamous and non-squamous histology
Neratinib Plus Capecitabine Outperforms Lapatinib Plus Capecitabine in Asian Patients with HER2-positive Metastatic Breast Cancer
Efficacy of the irreversible pan-HER tyrosine kinase inhibitor, neratinib, consistent with the results in the overall NALA population
Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive, HER2-negative Advanced Breast Cancer
Findings at 4-year follow-up in East Asian patients with advanced HR-positive, HER2-negative breast cancer are consistent with those in the overall MONARCH 2 study population
Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma Subtypes
The most widely used therapies and subsequent outcomes were identified with the aim of informing T-cell lymphoma treatment
Adding Olaparib to Bevacizumab Maintenance Improves Progression-Free Survival in Japanese Patients with Newly Diagnosed Advanced Ovarian Cancer
The Japan subset showed similar progression-free survival to the overall PAOLA-1 population